| http://www.w3.org/ns/prov#value | - The results of the phase 3 trial ??? called the Durable Response Therapy Evaluation for Early or New-Onset Type 1 Diabetes, or DEFEND-1 ??? sends researchers back to the drawing board in an attempt to use otelixizumab, an antibody created specifically to treat type 1 diabetes and other autoimmune diseases, to help maintain insulin function.
|
